SCYX - SCYNEXIS Inc Stock Price, Fair Value and News

1.79USD+0.07 (+4.07%)Market Closed

Market Summary

USD1.79+0.07

Market Closed

4.07%

SCYX Stock Price

View Fullscreen

SCYX RSI Chart

SCYX Valuation

Market Cap

67.6M

Price/Earnings (Trailing)

1.01

Price/Sales (Trailing)

0.48

EV/EBITDA

0.47

Price/Free Cashflow

1.12

SCYX Price/Sales (Trailing)

SCYX Profitability

Operating Margin

89.50%

EBT Margin

47.95%

Return on Equity

91.88%

Return on Assets

52.21%

Free Cashflow Yield

89.02%

SCYX Fundamentals

SCYX Revenue

Revenue (TTM)

140.1M

Rev. Growth (Yr)

282.01%

Rev. Growth (Qtr)

229.38%

SCYX Earnings

Earnings (TTM)

67.0M

Earnings Growth (Yr)

-35.74%

Earnings Growth (Qtr)

-1.0K%

Breaking Down SCYX Revenue

Last 7 days

21.8%

Last 30 days

23.5%

Last 90 days

-16.4%

Trailing 12 Months

-41.3%

How does SCYX drawdown profile look like?

SCYX Financial Health

Current Ratio

6.26

SCYX Investor Care

Shares Dilution (1Y)

13.29%

Diluted EPS (TTM)

1.36

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	38.9M	72.6M	106.4M	140.1M
2022	1.8M	3.1M	4.2M	5.1M
2021	5.5M	8.0M	10.6M	13.2M
2020	673.0K	476.0K	311.0K	2.9M
2019	394.5K	532.0K	669.5K	807.0K
2018	483.5K	672.5K	823.5K	257.0K
2017	221.0K	264.0K	325.0K	385.5K
2016	220.0K	195.0K	179.0K	180.0K
2015	1.3M	1.3M	1.3M	257.0K
2014	0	0	0	1.3M
2013	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of SCYNEXIS Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 16, 2024	sukenick scott	sold (taxes)	-24,741	1.63	-15,179	chief legal officer
Jan 26, 2024	macleod ivor	acquired	-	-	143,675	chief financial officer
Jan 26, 2024	angulo gonzalez david	acquired	-	-	290,590	chief executive officer
Jan 26, 2024	sukenick scott	acquired	-	-	143,675	chief legal officer
Jun 15, 2023	gilman steven c	acquired	-	-	10,000	-
Jun 15, 2023	macdonald guy	acquired	-	-	10,000	-
Jun 15, 2023	hanham ann	acquired	-	-	10,000	-
Jun 15, 2023	hastings david c	acquired	-	-	10,000	-
Jun 15, 2023	anido armando	acquired	-	-	10,000	-
Jun 15, 2023	tinmouth brian philippe	acquired	-	-	10,000	-

Which funds bought or sold SCYX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	PDS Planning, Inc	new	-	14,700	14,700	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 29, 2024	HighMark Wealth Management LLC	unchanged	-	-810	1,567	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	reduced	-4.41	-9,000	14,000	-%
Apr 25, 2024	Chicago Partners Investment Group LLC	reduced	-27.66	-37,348	58,681	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-13.56	-38,907	51,535	-%
Apr 24, 2024	Simplicity Wealth,LLC	new	-	29,400	29,400	-%
Apr 24, 2024	RITHOLTZ WEALTH MANAGEMENT	sold off	-100	-39,462	-	-%
Apr 22, 2024	WEALTH EFFECTS LLC	reduced	-2.55	-93,710	168,315	0.06%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	reduced	-5.95	-15,673	25,569	-%

Are Funds Buying or Selling SCYX?

Are funds buying SCYX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SCYX

No. of Funds

Unveiling SCYNEXIS Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	stonepine capital management, llc	3.6%	1,355,186	SC 13G/A
Feb 13, 2024	caxton corp	0%	0	SC 13G/A
Feb 13, 2024	avidity partners management lp	9.9%	3,968,816	SC 13G/A
Jan 18, 2024	federated hermes, inc.	19.99%	8,094,700	SC 13G/A
Nov 29, 2023	kingdon capital management, l.l.c.	6.02%	2,237,048	SC 13G/A
Jun 09, 2023	stonepine capital management, llc	7.6%	2,777,877	SC 13G
Apr 13, 2023	kingdon capital management, l.l.c.	5.1%	1,697,048	SC 13G
Apr 03, 2023	hirschman orin	3.5%	1,159,346	SC 13G/A
Feb 15, 2023	hirschman orin	5.3%	1,932,046	SC 13G/A
Feb 14, 2023	armistice capital, llc	4.72%	1,618,411	SC 13G/A

Recent SEC filings of SCYNEXIS Inc

View All Filings

Date Filed	Form Type	Document
Apr 25, 2024	DEFA14A	DEFA14A
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	ARS	ARS
Mar 28, 2024	S-8	Employee Benefits Plan
Mar 28, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report
Feb 16, 2024	4	Insider Trading
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to SCYNEXIS Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	360.8B	85.6B	-4.95%	-7.94%	9.38	4.21	5.68%	202.39%
MRK	324.7B	60.1B	-1.63%	8.46%	889.69	5.4	1.40%	-97.49%
PFE	156.4B	46.5B	0.51%	-27.98%	-112.61	3.36	42.59%	-114.62%
AMGN	149.2B	28.2B	0.79%	21.40%	22.21	5.29	7.09%	2.52%
GILD	81.4B	27.1B	-9.38%	-17.77%	14.37	3	-0.60%	23.36%
TEVA	15.7B	15.8B	1.44%	59.77%	-27.34	0.99	6.17%	76.47%
MID-CAP
PRGO	4.5B	4.7B	5.59%	-11.79%	-352.87	0.96	4.58%	90.97%
ALKS	4.0B	1.7B	-10.87%	-16.72%	9.29	2.34	54.01%	364.56%
BHC	3.0B	9.0B	-20.59%	9.46%	-6.53	0.33	10.01%	-27.45%
AMPH	2.1B	644.4M	0.80%	17.68%	14.92	3.18	29.14%	50.51%
SMALL-CAP
TLRY	1.6B	743.2M	-16.18%	-15.48%	-4.44	2.1	24.65%	80.36%
TXMD	21.8M	1.3M	-16.00%	-50.65%	-2.12	16.74	-98.14%	-109.18%
ACRX	17.1M	-	2.02%	57.81%	-0.93	0.22	2882.68%	-138.52%
AGRX	2.6M	19.6M	48.15%	-93.36%	-0.18	0.13	80.00%	43.08%
ACOR	1.1M	117.6M	-94.70%	-92.62%	0	0.01	-0.79%	-283.60%

SCYNEXIS Inc News

Latest updates

SCYNEXIS Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	229.4%	5,797,000	1,760,000	131,454,000	66,485,750	1,517,500	1,557,000	1,323,000	700,000	597,000	516,000	-	12,050,000	6,027,500	5,000	36,000	147,000	123,000	170,000	233,000	281,000	270,500
Operating Expenses	143.4%	28,861,500	11,859,000	14,940,000	11,812,000	24,004,500	23,358,000	23,061,000	20,425,000	22,893,000	19,957,000	17,508,000	13,644,000	15,335,000	11,511,000	11,826,000	12,479,000	14,107,500	11,756,000	11,253,000	11,925,000	8,854,500
S&GA Expenses	-28.4%	3,592,000	5,014,000	7,474,000	4,840,000	15,902,500	16,739,000	15,786,000	14,591,000	15,036,000	15,411,000	12,774,000	6,696,000	5,177,500	3,481,000	3,357,000	2,613,000	3,147,500	2,480,000	2,779,000	2,241,000	2,152,500
R&D Expenses	63.7%	10,586,500	6,466,000	7,040,000	6,835,000	7,906,000	6,430,000	7,131,000	5,735,000	7,690,000	4,401,000	4,734,000	6,948,000	10,157,500	8,030,000	8,469,000	9,866,000	10,960,000	9,276,000	8,474,000	9,684,000	6,702,000
EBITDA Margin	-30.3%	0.51	0.73	0.70	-2.19	-12.10	-18.43	-15.47	-21.24	-2.50	-4.46	-5.78	-9.83	-	-	-	-	-	-	-	-	-
Interest Expenses	4.7%	222,000	212,000	1,249,000	1,447,000	1,529,000	1,379,000	1,231,000	1,059,000	982,000	1,019,000	445,000	214,000	322,000	330,000	319,000	210,000	209,500	203,000	209,000	367,000	415,000
Income Taxes	-	138,000	-	-	-	-	-	-	-4,700,000	-	-50,000	-4,138,000	1,100,000	-4,000	-	-3,144,000	-	-	-	-	-	-
Earnings Before Taxes	-1005.7%	-19,427,000	-1,757,000	122,260,000	-33,876,000	-14,429,000	-29,584,000	-13,345,000	-10,151,000	-29,243,000	-655,000	-2,480,000	-3,576,000	-42,682,000	909,000	-9,525,000	-7,002,000	-14,458,000	-7,941,000	-8,403,000	-	-
EBT Margin	-29.3%	0.48	0.68	0.61	-2.35	-13.24	-19.71	-17.03	-23.46	-2.73	-4.66	-5.96	-10.07	-	-	-	-	-	-	-	-	-
Net Income	-1014.7%	-19,586,000	-1,757,000	122,260,000	-33,876,000	-14,429,000	-29,584,000	-13,345,000	-5,451,000	-29,243,000	-605,000	1,658,000	-4,676,000	-42,711,000	909,000	-6,381,000	-7,002,000	-14,458,000	-7,941,000	-8,403,000	-22,908,000	1,941,000
Net Income Margin	-29.5%	0.48	0.68	0.61	-2.35	-12.32	-18.58	-15.51	-18.56	-2.50	-4.37	-5.59	-9.70	-	-	-	-	-	-	-	-	-
Free Cashflow	-162.3%	-7,735,000	12,419,000	74,398,000	-18,923,000	-22,806,000	-22,508,000	-18,581,000	-15,988,000	-25,520,000	-16,586,000	-11,695,000	-759,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-13.6%	128	149	155	70.00	88.00	112	136	112	120	110	121	100	103	37.00	45.00	42.00	57.00	34.00	41.00	45.00	53.00
Current Assets	-20.6%	102	129	146	60.00	79.00	104	126	102	109	104	116	95.00	98.00	32.00	41.00	37.00	52.00	29.00	36.00	40.00	51.00
Cash Equivalents	-22.7%	34.00	44.00	58.00	27.00	46.00	69.00	119	95.00	105	100	113	92.00	93.00	30.00	34.00	21.00	42.00	12.00	19.00	13.00	12.00
Inventory	-100.0%	-	13.00	10.00	1.00	1.00	1.00	1.00	1.00	0.00	1.00	0.00	-	-	-	-	-	-	-	-	-	-
Net PPE	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00
Liabilities	-2.0%	55.00	57.00	62.00	100	85.00	95.00	90.00	73.00	79.00	72.00	89.00	74.00	80.00	27.00	39.00	35.00	44.00	28.00	31.00	34.00	22.00
Current Liabilities	-2.9%	16.00	17.00	16.00	46.00	18.00	14.00	16.00	13.00	14.00	13.00	20.00	25.00	26.00	8.00	7.00	7.00	11.00	8.00	7.00	5.00	6.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	15.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	15.00
Shareholder's Equity	-20.7%	73.00	92.00	93.00	-	3.00	17.00	45.00	39.00	41.00	38.00	32.00	26.00	23.00	10.00	6.00	6.00	13.00	6.00	10.00	11.00	31.00
Retained Earnings	-5.8%	-355	-335	-333	-456	-422	-407	-378	-364	-359	-330	-329	-331	-326	-283	-284	-278	-271	-256	-249	-240	-217
Additional Paid-In Capital	0.1%	428	428	427	426	425	425	424	404	401	368	362	357	349	293	291	285	284	263	259	252	249
Shares Outstanding	0.1%	37.00	37.00	37.00	33.00	33.00	41.00	38.00	32.00	29.00	27.00	26.00	26.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	109,140,501	-	-	-	60.00	-	-	-	169	-	-	-	78.00	-	-	-	70.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-162.3%	-7,735	12,419	74,398	-18,923	-22,806	-22,508	-18,581	-15,988	-25,520	-16,586	-11,695	-759	-16,572	-9,869	-8,856	-14,057	-13,458	-10,402	-7,758	-6,501	-6,058
Share Based Compensation	-11.9%	557	632	728	707	454	1,210	1,100	922	581	588	500	398	1,000	399	411	410	441	449	446	492	465
Cashflow From Investing	91.8%	-2,152	-26,341	-6,384	-	-	-27,380	-	-9.00	-583	-338	-51.00	-200	-	3,571	10,665	-7,762	10,044	-421	10,020	6,597	595
Cashflow From Financing	-497.1%	-135	34.00	-36,642	22.00	-	-183	42,062	6,723	30,478	4,533	32,180	-71.00	80,119	1,771	11,959	152	33,715	3,237	3,938	1,415	822

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SCYX Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue:
Total revenue	$ 140,141	$ 5,091
Operating expenses:
Cost of product revenue	15,624	628
Research and development	30,928	27,259
Selling, general and administrative	20,920	62,961
Total operating expenses	67,472	90,848
Income (loss) from operations	72,669	(85,757)
Other expense (income):
Amortization of debt issuance costs and discount	2,994	1,589
Interest income	(3,954)	(1,415)
Interest expense	3,130	5,198
Other income	0	(3)
Warrant liabilities fair value adjustment	3,166	(22,301)
Derivative liability fair value adjustment	154	(1,316)
Total other expense (income)	5,490	(18,248)
Income (loss) before taxes	67,179	(67,509)
Income tax (expense) benefit	(138)	4,700
Net income (loss)	$ 67,041	$ (62,809)
Net income (loss) per share attributable to common stockholders - basic
Net income (loss) per share -basic	$ 1.4	$ (1.47)
Net income (loss) per share attributable to common stockholders -diluted
Net income (loss) per share -diluted	$ 1.39	$ (1.47)
Weighted average common shares outstanding – basic and diluted
Basic	47,852,833	42,613,510
Diluted	48,390,582	42,613,510
Product Revenue, Net
Revenue:
Total revenue	$ 1,044	$ 4,988
License Agreement Revenue
Revenue:
Total revenue	$ 139,097	$ 103

SCYX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 34,050	$ 45,814
Short-term investments (See Note 3)	40,312	27,689
Prepaid expenses and other current assets (See Note 4)	5,548	2,503
License agreement receivable	2,463	0
License agreement contract asset	19,363	0
Accounts receivable, net	0	2,101
Inventory, net	0	899
Restricted cash	380	55
Total current assets	102,116	79,061
Investments (See Note 3)	23,594	0
Other assets	0	5,511
Deferred offering costs	175	73
Restricted cash	163	163
Intangible assets, net	0	408
Operating lease right-of-use asset (Note 9)	2,364	2,594
Total assets	128,412	87,810
Current liabilities:
Accounts payable	7,149	5,937
Accrued expenses (See Note 7)	7,495	5,628
Deferred revenue, current portion	1,189	0
Other liabilities, current portion (See Note 8)	0	5,771
Operating lease liability, current portion (Note 9)	340	282
Warrant liabilities	130	0
Total current liabilities	16,303	17,618
Deferred revenue	2,727	0
Warrant liabilities	21,680	18,644
Convertible debt and derivative liability (Note 8)	12,159	11,001
Loan payable (Note 8)	0	34,393
Operating lease liability (Note 9)	2,581	2,921
Total liabilities	55,450	84,577
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value, authorized 5,000,000 shares as of December 31, 2023 and December 31, 2022; 0 shares issued and outstanding as of December 31, 2023 and December 31, 2022	0	0
Common stock, $0.001 par value, 150,000,000 shares authorized as of December 31, 2023 and 2022; 37,207,799 and 32,682,342 shares issued and outstanding as of December 31, 2023, and December 31, 2022, respectively	40	36
Additional paid-in capital	428,169	425,485
Accumulated deficit	(355,247)	(422,288)
Total stockholders’ equity	72,962	3,233
Total liabilities and stockholders’ equity	$ 128,412	$ 87,810

About SCYNEXIS Inc

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of various fungal infections, including invasive candidiasis, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

CEO	Mr. David Gonzalez Angulo M.D.
WEBSITE	scynexis.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	36

SCYNEXIS Inc Frequently Asked Questions

What is the ticker symbol for SCYNEXIS Inc? What does SCYX stand for in stocks?

SCYX is the stock ticker symbol of SCYNEXIS Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of SCYNEXIS Inc (SCYX)?

As of Thu May 02 2024, market cap of SCYNEXIS Inc is 67.58 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SCYX stock?

You can check SCYX's fair value in chart for subscribers.

What is the fair value of SCYX stock?

You can check SCYX's fair value in chart for subscribers. The fair value of SCYNEXIS Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of SCYNEXIS Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SCYX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is SCYNEXIS Inc a good stock to buy?

The fair value guage provides a quick view whether SCYX is over valued or under valued. Whether SCYNEXIS Inc is cheap or expensive depends on the assumptions which impact SCYNEXIS Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SCYX.

What is SCYNEXIS Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, SCYX's PE ratio (Price to Earnings) is 1.01 and Price to Sales (PS) ratio is 0.48. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SCYX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on SCYNEXIS Inc's stock?

In the past 10 years, SCYNEXIS Inc has provided -0.323 (multiply by 100 for percentage) rate of return.